title: From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?
abstract: Major depressive disorder in adolescents is associated with significant morbidity and mortality. Major advances have been made in recent years in the treatment of adolescent depression, with promising outcomes. However, limitations of currently available treatments have prompted attempts to better understand pediatric depression from a broader perspective and to develop more effective treatment strategies in the future.
authors.affiliation: Hall-Mercer MH/MR Center, Pennsylvania Hospital, University of Pennsylvania Health System, 245 South 8th Street, Philadelphia, PA 19107, USA. zheya.yu@uphs.upenn.edu
authors.forename: Zheya Jenny
authors.initials: ZJ
authors.lastname: Yu
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kratochvil
authors.forename: Ronald A
authors.initials: RA
authors.lastname: Weller
authors.forename: Mira
authors.initials: M
authors.lastname: Mooreville
authors.forename: Elizabeth B
authors.initials: EB
authors.lastname: Weller
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000628:therapy*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D005473:Fluoxetine